Creative Planning’s Relmada Therapeutics RLMD Stock Holding History

Creative Planning’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$144K	Buy	+38,096	New	+$187K	﹤0.01%	4060
2022 Q4	–	Sell	-6,509	Closed	-$241K	–	2586
2022 Q3	$241K	Buy	+6,509	New	+$180K	﹤0.01%	1778
2021 Q3	–	Sell	-6,375	Closed	-$204K	–	2207
2021 Q2	$204K	Hold	6,375	–	–	﹤0.01%	1794
2021 Q1	$224K	Buy	+6,375	New	+$223K	﹤0.01%	2005

Other funds holding RLMD

Parsons Capital Management Providence, Rhode Island $2.29B AUM 21.99% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

MGO One Seven Beachwood, Ohio $6.08B AUM 21.44% 1-Year Est. Return

Apricus Wealth Beaufort, South Carolina $222M AUM 24.78% 1-Year Est. Return

Robertson Stephens Wealth Management San Francisco, California $4.14B AUM 13.63% 1-Year Est. Return

CV Advisors Aventura, Florida $594M AUM 18% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Creative Planning's RLMD Position: Q3 2026 in Review

Creative Planning opened a new position in Relmada Therapeutics (RLMD) in Q3 2026: 38,096 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #4060 among its holdings. This is a return to the name: Creative Planning previously reported a position in RLMD as recently as Q3 2022.

Creative Planning first reported a position in RLMD in Q1 2021 and has held it in 4 quarters since. The position peaked at $241K in Q3 2022. 18 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

Creative Planning held 38,096 shares of Relmada Therapeutics worth $144K as of Q3 2026.
Relmada Therapeutics was a new Creative Planning position in Q3 2026.
Relmada Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q3 2026, its #4060 holding.
Creative Planning first reported a position in Relmada Therapeutics in Q1 2021 and has held it in 4 quarters since.
Creative Planning's Relmada Therapeutics position peaked at $241K in Q3 2022.
18 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Creative Planning's 13F filing for Q3 2026, filed 2 Nov 2026.